SH2B3: A Drug Target / Disease Biomarker (G10019)

Target Name: SH2B3

NCBI ID: G10019

SH2B3

SH2B3: A Drug Target / Disease Biomarker

SH2B3, also known as S100 protein, is a protein that is expressed in a variety of tissues throughout the body. It is a member of the S100 family of proteins, which are known for their role in cell signaling and cytoplasmic organization. One of the unique features of SH2B3 is its ability to interact with other proteins, both within and outside of its own cell. This interactivity makes it an attractive candidate for drug targeting and as a biomarker for various diseases.

SH2B3 has been shown to play a role in a number of physiological processes, including cell adhesion, migration, and invasion. It is a critical regulator of the actinin-based protrusion of the cytoskeleton, which allows cells to move and change their shape. In addition, SH2B3 is involved in the regulation of cell death, and has been shown to play a role in the development and progression of cancer.

One of the key challenges in studying SH2B3 is its highly conserved nature. This has led to a lack of understanding of its underlying biology and a limited number of available studies. However, research into SH2B3 has identified a number of potential drug targets.

One of the most promising targets for SH2B3 is its role in cell signaling. SH2B3 has been shown to play a role in a variety of signaling pathways, including TGF-β, Hedgehog, and Wnt. These signaling pathways are involved in processes such as cell growth, differentiation, and survival, making them potential targets for drugs that can inhibit their activity.

Another potential target for SH2B3 is its role in cell adhesion. SH2B3 is involved in the regulation of cell-cell adhesion, which is critical for the maintenance of tissue structure and function. Drugs that can inhibit SH2B3 activity have been shown to be effective in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

In addition to its role in cell signaling and adhesion, SH2B3 has also been shown to be involved in the regulation of cell death. It is a critical regulator of apoptosis, which is the process by which cells undergo programmed cell death in response to environmental stressors. Abnormalities in cell death regulation have been implicated in a number of diseases, including cancer, neurodegenerative diseases, and depression.

The role of SH2B3 in cell death regulation makes it an attractive candidate for drug targeting. Drugs that can inhibit SH2B3 activity have been shown to be effective in a variety of diseases, including cancer, neurodegenerative diseases, and depression. In addition, the actinin-based protrusion of SH2B3 is also a potential target for drug intervention.

In conclusion, SH2B3 is a protein that has been shown to play a role in a variety of physiological processes, including cell adhesion, migration, and invasion. Its highly conserved nature and its involvement in multiple signaling pathways make it an attractive candidate for drug targeting. Further research is needed to fully understand its biology and develop effective drugs.

Protein Name: SH2B Adaptor Protein 3

Functions: Links T-cell receptor activation signal to phospholipase C-gamma-1, GRB2 and phosphatidylinositol 3-kinase

The "SH2B3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH2B3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets